India pharma patents quadruple to 2,995; drug pipeline hits 1,095 programmes
Synopsis
India's pharmaceutical sector has quietly engineered one of its most significant structural transitions: patent families originating from India have quadrupled in a decade, a drug pipeline of over 1,095 programmes is now active, and indigenous therapies like NexCAR19 are undercutting global CAR-T prices by 90%. The next five years, a BCG-HealthKois report warns, will decide whether this momentum hardens into a durable global innovation engine.
Key Takeaways
India-origin pharma patent families rose more than four-fold to 2,995 in 2024 , up from around 716 in 2015 .
The drug discovery pipeline now spans over 1,095 programmes across 195 companies .
India's share of global pharma patents grew from 3–4% to approximately 10% .
PE and VC investment in pharma more than doubled to $731 million in FY26 ; biotech startups rose from 1,500 to 2,400 .
Regulatory reforms cut drug development timelines from 180–270 days to 60–120 days .
Indigenous breakthroughs include BIRSA 101 (CRISPR therapy) and NexCAR19 (CAR-T therapy at one-tenth global cost).
India-origin pharmaceutical patent families have surged more than four-fold over the past decade, reaching 2,995 in 2024 from around 716 in 2015, while the country's drug discovery pipeline has expanded to over 1,095 programmes across 195 companies, according to a joint report released on 15 July 2025 by Boston Consulting Group (BCG) and HealthKois. The findings signal a structural shift in India's pharmaceutical sector — from generics-led manufacturing toward innovation-driven research.
Scale of the Shift
India's share of global pharma patents has climbed from 3–4 per cent to approximately 10 per cent, a gain the report describes as qualitative, not merely quantitative. The number of biotech startups in the country rose from nearly 1,500 to 2,400 over the same period. Private equity and venture capital investment in the pharmaceutical sector more than doubled to $731 million in FY26. India has also produced more than 10 novel drug assets over the past decade, with companies increasingly moving beyond generics and biosimilars to develop, license, and commercialise innovative medicines for global markets.
Key Drivers Behind the Momentum
The report identifies four forces powering this transition. First, nearly $5 billion in government funding has been directed toward early-stage and translational research. Second, stronger academia-industry collaboration has deepened the scientific talent pipeline. Third, regulatory reforms have cut drug development timelines from 180–270 days to 60–120 days. Fourth, shared research and manufacturing infrastructure — including Genome Valley and C-CAMP — has lowered barriers for emerging innovators.
Breakthrough Assets and Early Success Stories
The report highlights two landmark developments as evidence of India's maturing innovation capacity. BIRSA 101, described as India's first indigenously developed CRISPR-based therapeutic, represents a frontier leap in gene-editing medicine. NexCAR19, an indigenous CAR-T therapy, is priced at nearly one-tenth the cost of comparable overseas treatments, demonstrating that Indian innovation can combine scientific ambition with cost accessibility.
What Industry Leaders Said
Priyanka Aggarwal, Managing Director and Senior Partner at BCG India and Southeast Asia, said: 'India's innovation trajectory is gaining real momentum, and its evolution into a sustained innovation engine is well underway.'
Charles Janssen, Co-Founder and Managing Partner of HealthKois, added: 'We are seeing India-origin science licensed by global pharma majors and indigenous CAR-T therapies treating patients at a fraction of the global cost. Capital that understands the science and is willing to back it through the early, uncertain years will be the difference between a handful of breakout successes and a durable innovation engine.'
The Road Ahead
According to the report, the next five years will be decisive in determining whether India can convert its advantages — scientific talent, cost competitiveness, and large diverse patient datasets — into a globally competitive life sciences innovation ecosystem. The biggest opportunity, it argues, lies in building integrated innovation platforms rather than competing solely on frontier science. Whether capital deployment keeps pace with the pipeline's ambitions remains the central open question.
Point of View
But the BCG-HealthKois report is careful not to declare victory — and rightly so. Patent filings and active pipeline programmes are leading indicators, not outcomes; the real test is how many of these 1,095 programmes survive Phase II attrition and reach global markets. India's $731 million in pharma PE/VC investment, while growing, remains a fraction of what US or Chinese biotech ecosystems attract in a single quarter. The NexCAR19 and BIRSA 101 stories are compelling proof points, but two headline assets do not yet constitute a systemic innovation engine. The report's most pointed observation — that the next five years are decisive — is also an implicit warning: the window for building durable infrastructure, talent depth, and risk capital culture is open, but not indefinitely.
NationPress
15 Jul 2026
Frequently Asked Questions
How much have India-origin pharma patents grown in the last decade?
India-origin pharmaceutical patent families rose more than four-fold to 2,995 in 2024, up from around 716 in 2015, according to the BCG-HealthKois report released on 15 July 2025. India's share of global pharma patents also grew from 3–4% to approximately 10% over the same period.
What is the size of India's current drug discovery pipeline?
India's drug discovery pipeline has expanded to more than 1,095 active programmes across 195 companies, reflecting a broad-based shift from generics manufacturing toward original research and development.
What are BIRSA 101 and NexCAR19?
BIRSA 101 is described as India's first indigenously developed CRISPR-based therapeutic, representing a frontier advance in gene-editing medicine. NexCAR19 is an indigenous CAR-T therapy priced at nearly one-tenth the cost of comparable overseas treatments, illustrating India's ability to combine scientific innovation with cost accessibility.
What is driving India's pharmaceutical innovation surge?
The BCG-HealthKois report identifies four key drivers: nearly $5 billion in government funding for early-stage and translational research, stronger academia-industry collaboration, regulatory reforms that cut drug development timelines from 180–270 days to 60–120 days, and shared infrastructure such as Genome Valley and C-CAMP.
How much has investment in Indian pharma grown?
Private equity and venture capital investment in India's pharmaceutical sector more than doubled to $731 million in FY26, while the number of biotech startups rose from nearly 1,500 to 2,400 over the past decade, according to the report.
